Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment.
Ponticelli
Claudio
C
Locatelli
Francesco
F
D000818:Animals; D004195:Disease Models, Animal; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D000068338:Everolimus; D005919:Glomerular Filtration Rate / Q000502:physiology; D006801:Humans; D009154:Mutation / Q000235:genetics; D019869:Phosphatidylinositol 3-Kinases / Q000502:physiology; D016891:Polycystic Kidney, Autosomal Dominant / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D051381:Rats; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D050396:TRPP Cation Channels / Q000235:genetics
D000068338:Everolimus; D019869:Phosphatidylinositol 3-Kinases; D020123:Sirolimus; D058570:TOR Serine-Threonine Kinases; D050396:TRPP Cation Channels; C546842:MTOR protein, human